Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
about
Contemporary approaches for imaging skeletal metastasisTheragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitorsSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsNoninvasive imaging of cardiovascular injury related to the treatment of cancerTheranostic applications of antibodies in oncology.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsAntibody-based imaging of HER-2: moving into the clinic.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabTargeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseNuclear imaging in detection and monitoring of cardiotoxicity.Near infrared fluorescent optical imaging for nodal staging.A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumorA pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancerNuclear imaging: a powerful novel approach for tuberculosis.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentImmunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CTExogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives.Receptor conversion in distant breast cancer metastasesDevelopment of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.The next generation of positron emission tomography radiopharmaceuticals in oncology.Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Recent trends in antibody-based oncologic imagingA comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapyStroma targeting nuclear imaging and radiopharmaceuticals.Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncologyA phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients.Targeted molecular imaging in oncology: focus on radiation therapy.Cardiac side effects of anticancer treatments: new mechanistic insightsThe evolving role of nuclear molecular imaging in cancer.
P2860
Q26798170-8EF6A3DF-7154-41ED-A2AB-8BE12CE42D36Q26824717-9B288AF6-8F8B-4114-BD41-9B0F10CAB913Q27007849-4D94A604-D834-4027-A6DB-96F124E817CAQ27024715-4CC7CAF8-2142-4EA8-BAC0-F927FDF29C24Q27693293-DACCA69D-CE70-4D9B-B440-AC92382F2C63Q28087776-8FB643EC-1F79-455A-B29D-0A3C5366C5CCQ30423880-3D552D22-037D-492A-9F1B-081F5D97F380Q30427656-C10B0A89-32BC-4887-A33D-3CD30BDA622DQ33527397-0C57FA10-A33E-4668-846C-65EED59C1CA9Q33661325-B6E34585-A91C-422E-98F4-3621CABDAC2EQ33696408-90B4A405-7FC8-4CDB-A48A-53558F1031B8Q33854382-086B60A4-16FF-46C9-A7DD-022A731625EAQ33870879-8FC7591E-58E0-44A3-9852-CDE898EBF1A7Q33942611-768E3680-4DD4-40DF-B191-1355940B41A8Q34038991-67099861-EBF2-48DB-8D50-738D5D644907Q34134371-DDBDC81C-A03A-4D7E-B103-F459FF15A961Q34218621-4B3AC5C2-4BF5-4DA2-906E-0BE6C5EED9E9Q34315731-3E1B4072-BCF2-41EE-A56E-2B8882729F66Q34466688-1713A219-1FCD-4C05-8F6C-46C793DEA95FQ34519479-60FC6070-07FA-4D7F-98A9-5CA2A543D976Q34694211-16D4E446-1517-4CD7-8312-77AB1B5AB883Q34787997-FA7DBE66-9F04-4AFF-A287-50A3B74EF8B7Q34954961-7A171D5F-995E-44C8-8582-347391ACDB1EQ34989060-97B85C8A-5577-4AF0-AC40-D6817448D1E9Q35043734-F3243EA2-BCBD-4573-BA2A-E47BBEB64C93Q35170338-FCFEAB07-E288-47FD-89BD-127F392CC8B7Q35184816-F4D03252-0627-4F11-BF4A-67A8A823C4E5Q35525690-DB2FDFFD-C8F3-4ECC-9936-9291CF5D8FB9Q35588736-EF46B614-D8ED-476E-BC7D-083FD485B204Q35643425-ADCBE144-7BEE-45A1-A3D3-842261262B3BQ35650526-8FE50CDD-4263-43C1-8FE1-BC297107CED7Q35793157-E1A4D68C-45AB-483B-9EDD-0B131510E10AQ35999606-1A243748-3F47-4A69-A715-D95993B9D8A1Q36100348-6ECC6AD1-6E2D-48E1-8AD8-CC0529AA4FAFQ36324211-AF5F04D7-54AE-4F97-9160-AA687135C542Q36339722-206F0457-1582-479D-9A6E-36117DE51466Q36396272-BE7078AA-D1C9-4D83-99FE-8289A8A28108Q36528175-B3A50A55-D40B-4D5E-9FFC-517685EB6373Q36957758-C2068625-F419-4A4B-9AC6-05E732426479Q37011086-0DF50256-78D9-4B1E-BD6E-A8C4D31E6F51
P2860
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@en
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@nl
type
label
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@en
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@nl
prefLabel
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@en
Indium-111-labeled trastuzumab ...... tive metastatic breast cancer.
@nl
P2093
P356
P1476
Indium-111-labeled trastuzumab ...... itive metastatic breast cancer
@en
P2093
Dirk J van Veldhuisen
Dirk T Sleijfer
Jos G W Kosterink
M Alexander de Korte
Marjolijn N Lub-De Hooge
Patrick J Perik
Pieter L Jager
Sharon Jonkman
Winette T A van der Graaf
P304
P356
10.1200/JCO.2005.03.8448
P407
P577
2006-05-01T00:00:00Z